Elicio Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
ELTX$1.61-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(11,827) | $(8,029) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 82 | 110 |
| Amortization of right-of-use assets, operating leases | 208 | — |
| Non-cash interest expense | — | 342 |
| Change in fair value of embedded derivative | — | (108) |
| Change in fair value of warrant liability | 1,278 | — |
| Stock-based compensation expense | 324 | 224 |
| Loss on issuance of warrants | 578 | — |
| Gain on sale of property and equipment | (3) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,085 | (1,215) |
| Other long-term prepaid assets | 160 | 197 |
| Accounts payable | (3,264) | 1,385 |
| Accrued expenses and other current liabilities | (432) | (375) |
| Deferred research obligation | (67) | (507) |
| Operating lease liabilities | (244) | (163) |
| Net cash used in operating activities | (12,122) | (8,139) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | — | (17) |
| Proceeds from sale of property and equipment | 3 | — |
| Net cash provided by (used in) investing activities | 3 | (17) |
| Cash flows from financing activities | ||
| Proceeds from issuance of promissory notes payable | — | 10,000 |
| Proceeds from issuance of common stock warrants | 5,962 | — |
| Proceeds from issuance of common stock | 5,062 | — |
| Exercise of stock options | — | 40 |
| Net cash provided by financing activities | 11,024 | 10,040 |
| Net (decrease) increase in cash and cash equivalents | (1,095) | 1,884 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 14,301 | 8,414 |
| Cash, cash equivalents and restricted cash at the end of the period | $13,206 | $10,298 |
| Components of cash, cash equivalents, and restricted cash | ||
| Cash and cash equivalents | $11,853 | $8,572 |
| Restricted cash | 1,353 | 1,726 |
| Total cash, cash equivalents and restricted cash | $13,206 | $10,298 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Fair value at issuance of March Pre-Funded Warrants | $6,579 | $— |
| Accretion of promissory note discount from embedded derivative | $— | $57 |
| Accretion of promissory note to face value | $— | $274 |
| Non-cash vesting of restricted common stock | $11 | $34 |
| Interest expense from convertible notes payable | $— | $14 |
| Accretion of convertible notes discount from issuance costs | $— | $173 |
=
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.